As a result of significant recent developments, the management of patients with chronic
lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to …

Background The clinical course of patients with chronic lymphocytic leukemia (CLL) is
heterogeneous, with some patients experiencing rapid disease progression and others …

In addition to clinical staging, a number of biomarkers predicting overall survival (OS) have
been identified in chronic lymphocytic leukemia (CLL). The multiplicity of markers, limited …

Purpose The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse;
some patients have indolent disease, never needing treatment, whereas others have …

Waldenström's macroglobulinemia is a disease of mature B cells, the genetic basis of which
is poorly understood. Few recurrent chromosomal abnormalities have been reported, and …

The heterogeneity of early stage CLL challenges prognostication, and refinement of
prognostic indices for risk-adapted management in this population is essential. The aim of …

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a variable clinical
course. The Rai and Binet staging systems are often used to predict survival. However, they …

Chromosomal abnormalities are frequently observed in patients with chronic lymphocytic
leukemia (CLL) and have prognostic value. Deletions of the short arm of chromosome 17 …

Background Chronic lymphocytic leukaemia (CLL) is the most common cancer of the
lymphatic system in Western countries. Several clinical and biological factors for CLL have …

B-cell antigen receptor (BCR)–mediated signaling plays a critical role in chronic lymphocytic
leukemia (CLL) pathogenesis and gives an in vitro survival advantage to B cells isolated …